Atara Biotherapeutics, Inc. (ATRA)
Develops cell therapies treating cancer and autoimmune diseases after organ transplants.
$7.81+0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-32.4%
The outlook
ATRA is trading well below its 50- and 200-day moving averages and sits near the lower end of its 52-week range. Analyst sentiment leans bearish overall, though the average price target implies roughly 75% upside from current levels. The stock shows mixed signals between near-term momentum and longer-term analyst expectations.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range26% of the way from its 52-week low to high
Price targetAvg target +75% vs current price
Analyst price target
~12-month · 3 analysts$13.67average target+75.0% vs now
Now $7.81
Low $10.00High $18.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$70.4M
52-wk high
$19.15
52-wk low
$3.92
50-day avg
$9.76
200-day avg
$9.57
Trailing P/E
—